Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers | News Direct

Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

Context Therapeutics
Digital Asset Direct by Context Therapeutics
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon New York, New York | December 06, 2022 03:40 AM Pacific Standard Time

Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studio to discuss its lead T cell-engaging bispecific antibody clinical development candidate to target Claudin 6 (CLDN6) positive cancers. Lehr says CTIM-76 is a CLDN6 x CD3 bispecific antibody that shows high selectivity for ovarian, endometrial, testicular, and gastric cancers.

 

Contact Details

 

Proactive Investors USA

 

Proactive Investors USA

 

+1 347-449-0879

 

na-editorial@proactiveinvestors.com

DOWNLOAD

project media

Tags

contexttherapeuticsproactivebiotechpharmacancertreatmenthealthstockinvestmentnasdaq
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.